WO2004081026A2
(en)
*
|
2003-06-30 |
2004-09-23 |
Domantis Limited |
Polypeptides
|
EP2366718A3
(en)
*
|
2002-06-28 |
2012-05-02 |
Domantis Limited |
Ligand
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
JP2008507294A
(ja)
|
2004-07-26 |
2008-03-13 |
ダウ グローバル テクノロジーズ インコーポレイティド |
菌株遺伝子操作による改善されたタンパク質発現のための方法
|
RS20070027A
(en)
|
2004-07-26 |
2008-11-28 |
Biogen Idec Ma Inc., |
Anti-cd154 antibodies
|
US7563443B2
(en)
*
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
GB0521621D0
(en)
|
2005-10-24 |
2005-11-30 |
Domantis Ltd |
Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
|
US20090214534A1
(en)
*
|
2004-12-02 |
2009-08-27 |
Steve Holmes |
Bispecific Domain Antibodies Targeting Serum Albumin And GLP-1 Or PYY
|
MX2007011356A
(es)
*
|
2005-03-18 |
2008-03-10 |
Domantis Ltd |
Anticuerpos contra antigenos de candida.
|
ES2592271T3
(es)
|
2005-03-31 |
2016-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
|
LT1868635T
(lt)
|
2005-04-06 |
2017-07-10 |
Bristol-Myers Squibb Company |
Imuninių sutrikimų, susijusių su transplantato persodinimu, gydymo būdas tirpiomis mutantinėmis ctla4 molekulėmis
|
EP1888640B1
(en)
|
2005-05-18 |
2012-03-14 |
Ablynx N.V. |
Improved nanobodies against tumor necrosis factor-alpha
|
EP2532679B1
(en)
*
|
2005-10-21 |
2017-04-12 |
Novartis AG |
Human antibodies against il13 and therapeutic uses
|
UA96139C2
(uk)
*
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
EP4342995A3
(en)
|
2006-03-31 |
2024-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
EP4218801A3
(en)
|
2006-03-31 |
2023-08-23 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
CA2652599C
(en)
*
|
2006-05-03 |
2019-09-24 |
Ross Kedl |
Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
|
EP1854810A1
(en)
*
|
2006-05-09 |
2007-11-14 |
PanGenetics B.V. |
Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
|
JP2009536527A
(ja)
*
|
2006-05-09 |
2009-10-15 |
ジェネンテック・インコーポレーテッド |
最適化されたスキャフォールドを備えた結合ポリペプチド
|
WO2007149567A2
(en)
|
2006-06-21 |
2007-12-27 |
Musc Foundation For Research Development |
Targeting complement factor h for treatment of diseases
|
US9512236B2
(en)
|
2006-12-19 |
2016-12-06 |
Ablynx N.V. |
Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
|
WO2008074839A2
(en)
|
2006-12-19 |
2008-06-26 |
Ablynx N.V. |
Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
|
US9156914B2
(en)
|
2006-12-19 |
2015-10-13 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
|
JP5721951B2
(ja)
|
2007-03-22 |
2015-05-20 |
バイオジェン アイデック マサチューセッツ インコーポレイテッド |
抗体、抗体誘導体、および抗体断片を含む、cd154に特異的に結合する結合タンパク質ならびにその使用
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
JP5444553B2
(ja)
|
2007-04-27 |
2014-03-19 |
フェネックス インコーポレイテッド |
微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および/または質が改善されている特定の株を同定する方法
|
CA2691940C
(en)
|
2007-07-03 |
2018-03-06 |
Joost Alexander Kolkman |
Methods for providing improved immunoglobulin sequences
|
AR068563A1
(es)
|
2007-09-26 |
2009-11-18 |
Chugai Pharmaceutical Co Ltd |
Region constante de anticuerpo mutante
|
WO2009041643A1
(ja)
|
2007-09-26 |
2009-04-02 |
Chugai Seiyaku Kabushiki Kaisha |
Cdrのアミノ酸置換により抗体の等電点を改変する方法
|
US20110189203A1
(en)
|
2007-11-27 |
2011-08-04 |
Ablynx N.V. |
Immunoglobulin constructs
|
ES2585480T3
(es)
|
2007-12-05 |
2016-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Anticuerpo anti-NR10 y uso del mismo
|
EP2247616A2
(en)
|
2008-03-05 |
2010-11-10 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making and uses thereof
|
GB0809069D0
(en)
|
2008-05-19 |
2008-06-25 |
Univ Leuven Kath |
Gene signatures
|
CA2720763A1
(en)
|
2008-04-07 |
2009-10-15 |
Ablynx Nv |
Amino acid sequences directed against the notch pathways and uses thereof
|
JP2011516603A
(ja)
|
2008-04-17 |
2011-05-26 |
アブリンクス エン.ヴェー. |
血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
|
EP2285833B1
(en)
|
2008-05-16 |
2014-12-17 |
Ablynx N.V. |
AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
|
TW201006485A
(en)
*
|
2008-06-03 |
2010-02-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
SI2285408T1
(sl)
|
2008-06-05 |
2019-02-28 |
Ablynx N.V. |
Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni
|
WO2010003193A1
(en)
*
|
2008-07-11 |
2010-01-14 |
Phylogica Limited |
Peptide inhibitors of cd40l signaling and uses therefor
|
US20110097339A1
(en)
*
|
2008-07-18 |
2011-04-28 |
Domantis Limited |
Compositions monovalent for CD28 binding and methods of use
|
EP2315778A2
(en)
*
|
2008-07-18 |
2011-05-04 |
Domantis Limited |
Compositions monovalent for cd28 binding and methods of use
|
US20100136584A1
(en)
*
|
2008-09-22 |
2010-06-03 |
Icb International, Inc. |
Methods for using antibodies and analogs thereof
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
WO2010043650A2
(en)
|
2008-10-14 |
2010-04-22 |
Ablynx Nv |
Amino acid sequences directed against cellular receptors for viruses and bacteria
|
US9044459B2
(en)
|
2008-12-05 |
2015-06-02 |
Als Therapy Development Institute |
Method for the treatment of neurodegenerative diseases
|
JP2012511014A
(ja)
*
|
2008-12-05 |
2012-05-17 |
エイエルエス・セラピー・デベロップメント・インスティテュート |
神経変成疾患を治療する方法
|
WO2010066836A2
(en)
|
2008-12-10 |
2010-06-17 |
Ablynx Nv |
Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
|
MX2011007030A
(es)
*
|
2008-12-30 |
2011-07-20 |
Centocor Ortho Biotech Inc |
Marcadores sericos que predicen la respuesta clinica a los anticuerpos anti-factor de necrosis tumoral alfa en pacientes con espondilitis anquilosante.
|
EP2210902A1
(en)
*
|
2009-01-14 |
2010-07-28 |
TcL Pharma |
Recombinant monovalent antibodies
|
EP2403873A1
(en)
|
2009-03-05 |
2012-01-11 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
WO2011026948A1
(en)
|
2009-09-03 |
2011-03-10 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
EP3674317A1
(en)
|
2009-03-19 |
2020-07-01 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
WO2010107110A1
(ja)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
抗体定常領域改変体
|
CN105399828B
(zh)
|
2009-04-10 |
2021-01-15 |
埃博灵克斯股份有限公司 |
用于治疗il-6r相关疾病和病症的改进的针对il-6r的氨基酸序列和包含其的多肽
|
PL2424889T3
(pl)
|
2009-04-30 |
2016-01-29 |
Ablynx Nv |
Sposób wytwarzania przeciwciał domenowych
|
BRPI1011145A2
(pt)
|
2009-05-15 |
2016-03-15 |
Chugai Pharmaceutical Co Ltd |
anticorpo anti-axl
|
PL2896404T3
(pl)
*
|
2009-06-04 |
2017-12-29 |
Novartis Ag |
Sposoby identyfikacji miejsc koniugacji IgG
|
HUE035773T2
(en)
|
2009-06-05 |
2018-05-28 |
Ablynx Nv |
Trivalent human airway giant cell virus (hrsv) nanotubes for preventing and / or treating respiratory infections
|
JP5871798B2
(ja)
|
2009-07-02 |
2016-03-01 |
エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント |
肝再生を刺激する方法
|
EP2451839B1
(en)
|
2009-07-10 |
2020-04-22 |
Ablynx N.V. |
Method for the production of variable domains
|
WO2011006915A2
(en)
*
|
2009-07-16 |
2011-01-20 |
Glaxo Group Limited |
Improved anti-serum albumin binding single variable domains
|
EP2459593A2
(en)
*
|
2009-07-29 |
2012-06-06 |
Glaxo Group Limited |
Anti-tgf-beta receptor type ii single domain antibodies
|
AU2010299640B2
(en)
|
2009-09-24 |
2016-02-25 |
Ucb Pharma S.A. |
Bacterial host strain
|
WO2011037158A1
(ja)
|
2009-09-24 |
2011-03-31 |
中外製薬株式会社 |
抗体定常領域改変体
|
CA2795311A1
(en)
|
2009-11-05 |
2011-05-12 |
Taligen Therapeutics, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
|
US20120269814A1
(en)
*
|
2009-11-10 |
2012-10-25 |
Amgen Inc. |
Anti-c mpl antibodies
|
WO2011064382A1
(en)
|
2009-11-30 |
2011-06-03 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
WO2011073180A1
(en)
|
2009-12-14 |
2011-06-23 |
Ablynx N.V. |
Single variable domain antibodies against ox40l, constructs and therapeutic use
|
WO2011083141A2
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Method for generation of immunoglobulin sequences by using lipoprotein particles
|
GB201000587D0
(en)
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial hoist strain
|
GB201000591D0
(en)
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial hoist strain
|
GB201000590D0
(en)
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial host strain
|
WO2011095545A1
(en)
|
2010-02-05 |
2011-08-11 |
Ablynx Nv |
Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
ES2931330T3
(es)
|
2010-02-11 |
2022-12-28 |
Ablynx Nv |
Métodos y composiciones para la preparación de aerosoles
|
EP2543730B1
(en)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
US8937164B2
(en)
|
2010-03-26 |
2015-01-20 |
Ablynx N.V. |
Biological materials related to CXCR7
|
US20130101590A1
(en)
|
2010-04-09 |
2013-04-25 |
Heather A. Arnett |
Btnl9 proteins, nucleic acids, and antibodies and uses thereof
|
EP2569332B1
(en)
|
2010-05-14 |
2019-01-09 |
The Regents of the University of Colorado, A Body Corporate |
Improved complement receptor 2 (cr2) targeting groups
|
CN102906118B
(zh)
|
2010-05-20 |
2017-07-28 |
埃博灵克斯股份有限公司 |
与her3相关的生物材料
|
KR20130036276A
(ko)
|
2010-06-22 |
2013-04-11 |
더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 |
보체 결합 3의 C3d 조각에 대한 항체들
|
WO2011161263A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Pharmaceutical compositions for cutaneous administration
|
CN103097418A
(zh)
|
2010-07-09 |
2013-05-08 |
霍夫曼-拉罗奇有限公司 |
抗神经毡蛋白抗体及使用方法
|
GB201012599D0
(en)
|
2010-07-27 |
2010-09-08 |
Ucb Pharma Sa |
Process for purifying proteins
|
EP2621953B1
(en)
|
2010-09-30 |
2017-04-05 |
Ablynx N.V. |
Biological materials related to c-met
|
KR101853405B1
(ko)
*
|
2010-10-20 |
2018-05-02 |
주식회사 티움바이오 |
인자 ix 활성을 갖는 융합 단백질
|
ES2660895T3
(es)
|
2010-10-29 |
2018-03-26 |
Ablynx N.V. |
Método para la producción de dominios variables individuales de inmunoglobulina
|
BR112013011811A2
(pt)
|
2010-11-05 |
2023-02-23 |
Zymeworks Inc |
Modelo de anticorpo heterodimérico estável com mutações no domínio fc
|
JP5933573B2
(ja)
|
2010-11-08 |
2016-06-15 |
ノバルティス アーゲー |
Cxcr2結合ポリペプチド
|
PT2644698T
(pt)
|
2010-11-17 |
2018-01-31 |
Chugai Pharmaceutical Co Ltd |
Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue
|
WO2012072731A2
(en)
*
|
2010-12-01 |
2012-06-07 |
Glaxo Group Limited |
Improved anti-serum albumin binding single variable domains
|
US20140093496A1
(en)
|
2011-02-25 |
2014-04-03 |
Chugai Seiyaku Kabushiki Kaisha |
Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
|
PT2691415T
(pt)
|
2011-03-28 |
2018-10-19 |
Ablynx Nv |
Método para produção de formulações sólidas compreendendo domínios variáveis únicos de imunoglobulina
|
US20150158948A9
(en)
|
2011-03-28 |
2015-06-11 |
Francis Descamps |
Bispecific anti-cxcr7 immunoglobulin single variable domains
|
AR086360A1
(es)
|
2011-04-21 |
2013-12-11 |
Bristol Myers Squibb Co |
Polipeptidos anticuerpos que antagonizan cd40
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
US9534039B2
(en)
|
2011-05-09 |
2017-01-03 |
Ablynx N.V. |
Method for the production of immunoglobulin single variable domains
|
RU2661677C2
(ru)
|
2011-05-27 |
2018-07-18 |
Аблинкс Нв |
Ингибирование резорбции кости с помощью связывающих rank-l пептидов
|
JP2014525736A
(ja)
|
2011-06-23 |
2014-10-02 |
アブリンクス エン.ヴェー. |
IgEに対する免疫グロブリン単一可変ドメイン
|
EP3339325A1
(en)
|
2011-07-13 |
2018-06-27 |
UCB Biopharma SPRL |
Bacterial host strain expressing recombinant dsbc
|
PE20141659A1
(es)
|
2011-07-27 |
2014-11-21 |
Glaxo Group Ltd |
Dominios variables singulares anti-vgf fusionados con dominios de fc
|
JP6297976B2
(ja)
*
|
2011-08-17 |
2018-03-20 |
グラクソ グループ リミテッドGlaxo Group Limited |
改変タンパク質およびペプチド
|
DK2747782T3
(en)
|
2011-09-23 |
2018-04-23 |
Ablynx Nv |
Long-term inhibition of interleukin-6-mediated signal transmission
|
EP2762493B1
(en)
|
2011-09-30 |
2021-06-09 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
JP6219287B2
(ja)
|
2011-09-30 |
2017-10-25 |
アブリンクス エン.ヴェー. |
c−Metに関連する生物学的物質
|
TW201326209A
(zh)
|
2011-09-30 |
2013-07-01 |
Chugai Pharmaceutical Co Ltd |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
TWI585102B
(zh)
|
2011-10-13 |
2017-06-01 |
必治妥美雅史谷比公司 |
拮抗cd40l之抗體多肽
|
RS62689B1
(sr)
|
2011-11-04 |
2021-12-31 |
Zymeworks Inc |
Dizajn stabilnog heterodimernog antitela sa mutacijama u fc domenu
|
AU2012340624B2
(en)
|
2011-11-23 |
2017-08-24 |
Amgen Inc. |
Methods of treatment using an antibody against interferon gamma
|
CA2872540A1
(en)
|
2012-05-10 |
2013-11-14 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
DK3207938T3
(da)
*
|
2012-05-11 |
2020-03-16 |
Medimmune Ltd |
Ctla-4-varianter
|
GB201208367D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Biological product
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
CN104703999A
(zh)
|
2012-07-19 |
2015-06-10 |
安姆根有限公司 |
人btnl3蛋白、核酸和抗体及其用途
|
US10413620B2
(en)
|
2012-08-17 |
2019-09-17 |
The Regents Of The University Of Colorado, A Body Corporate |
Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
|
AU2013302441B2
(en)
|
2012-08-17 |
2018-05-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for detecting complement activation
|
EP2906683B1
(en)
|
2012-10-15 |
2017-05-31 |
Bristol-Myers Squibb Company |
Mammalian cell culture processes for protein production
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
JP6392770B2
(ja)
*
|
2012-12-03 |
2018-09-19 |
ノビミューン エスアー |
抗cd47抗体およびその使用方法
|
JP6967347B2
(ja)
|
2013-04-29 |
2021-11-17 |
バイオタリス・エン・フェー |
スフィンゴ脂質に結合する抗体を含む農薬組成物
|
AU2014325063B2
(en)
|
2013-09-27 |
2019-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide heteromultimer
|
EP2883883A1
(en)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutic targets and agents useful in treating ischemia reperfusion injury
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
WO2015134988A1
(en)
|
2014-03-07 |
2015-09-11 |
Bristol-Myers Squibb Company |
Method of using antibody polypeptides that antagonize cd40 to treat ibd
|
NL2013007B1
(en)
|
2014-06-16 |
2016-07-05 |
Ablynx Nv |
Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
US10512739B2
(en)
|
2014-10-10 |
2019-12-24 |
Vectura Gmbh |
Inhalation device for use in aerosol therapy of respiratory diseases
|
RU2017115670A
(ru)
|
2014-10-10 |
2018-11-15 |
Аблинкс Н.В. |
Лечение инфекции рсв
|
EP3215624B1
(en)
|
2014-11-05 |
2023-11-29 |
Biotalys NV |
Transgenic plant comprising a polynucleotide encoding a variable domain of heavy-chain antibody
|
KR102656470B1
(ko)
|
2014-12-10 |
2024-04-09 |
리전츠 오브 더 유니버스티 오브 미네소타 |
질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기
|
MY181199A
(en)
|
2014-12-19 |
2020-12-21 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
EA201791366A1
(ru)
|
2014-12-19 |
2018-02-28 |
Чугаи Сейяку Кабусики Кайся |
Антитела к c5 и способы их применения
|
PL3233910T3
(pl)
|
2014-12-19 |
2020-06-01 |
Ablynx N.V. |
Dimery nanociał połączone cysteiną
|
GB201501613D0
(en)
|
2015-01-30 |
2015-03-18 |
Ucb Biopharma Sprl |
Treatment of autoimmune disorders with CD154 antibodies
|
US10544210B2
(en)
|
2015-02-03 |
2020-01-28 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-Rho GTPase conformational single domain antibodies and uses thereof
|
MA41459A
(fr)
|
2015-02-03 |
2017-12-12 |
Als Therapy Development Inst |
Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
|
CN107108729A
(zh)
|
2015-02-05 |
2017-08-29 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il‑8‑结合抗体,及其应用
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
BR112017014067B1
(pt)
|
2015-02-27 |
2021-01-12 |
Chugai Seiyaku Kabushiki Kaisha |
usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
US9434785B1
(en)
|
2015-04-30 |
2016-09-06 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
|
US9512229B2
(en)
|
2015-03-03 |
2016-12-06 |
Kymab Limited |
Synergistic combinations of OX40L antibodies for the treatment of GVHD
|
WO2016159213A1
(ja)
|
2015-04-01 |
2016-10-06 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
MA42043A
(fr)
|
2015-05-07 |
2018-03-14 |
Agenus Inc |
Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
|
EP3611192A3
(en)
|
2015-05-13 |
2020-03-25 |
Ablynx N.V. |
T cell recruiting polypeptides based on tcr alpha/beta reactivity
|
AU2016260909B2
(en)
|
2015-05-13 |
2019-08-22 |
Ablynx N.V. |
T cell recruiting polypeptides based on CD3 reactivity
|
JP7049988B2
(ja)
|
2015-08-05 |
2022-04-07 |
ヤンセン バイオテツク,インコーポレーテツド |
抗cd154抗体及びこれを使用する方法
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
US20170059561A1
(en)
*
|
2015-08-28 |
2017-03-02 |
The Florida International University Board Of Trustees |
Thermally Stable Electrochemical Sensor With Long Shelf-Life
|
EP3350212A1
(en)
|
2015-09-18 |
2018-07-25 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
T cell receptors (tcr) and uses thereof for the diagnosis and treatment of diabetes
|
ES2839212T3
(es)
|
2015-09-29 |
2021-07-05 |
Inst Nat Sante Rech Med |
Métodos para determinar el estado metabólico de linfomas B
|
US10556953B2
(en)
|
2015-10-12 |
2020-02-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction
|
WO2017081190A1
(en)
|
2015-11-13 |
2017-05-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti- nkg2d single domain antibodies and uses thereof
|
SG11201803976VA
(en)
|
2015-11-27 |
2018-06-28 |
Ablynx Nv |
Polypeptides inhibiting cd40l
|
US11447557B2
(en)
|
2015-12-02 |
2022-09-20 |
Agenus Inc. |
Antibodies and methods of use thereof
|
US11359009B2
(en)
|
2015-12-25 |
2022-06-14 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
EP3398965A4
(en)
|
2015-12-28 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION
|
ES2837155T3
(es)
|
2016-01-04 |
2021-06-29 |
Inst Nat Sante Rech Med |
Uso de PD-1 y Tim-3 como medida de células CD8+ para predecir y tratar el carcinoma de células renales
|
WO2017129558A1
(en)
|
2016-01-25 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
|
US10918737B2
(en)
|
2016-01-28 |
2021-02-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancer
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
JP6902040B2
(ja)
|
2016-01-28 |
2021-07-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
免疫チェックポイント阻害剤の効力を増強する方法
|
SG11201807936VA
(en)
|
2016-03-14 |
2018-10-30 |
Chugai Pharmaceutical Co Ltd |
Cell injury inducing therapeutic drug for use in cancer therapy
|
EP3439659A1
(en)
|
2016-04-06 |
2019-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases
|
WO2017182609A1
(en)
|
2016-04-22 |
2017-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency
|
US20190127447A1
(en)
|
2016-05-02 |
2019-05-02 |
Ablynx N.V. |
Treatment of rsv infection
|
JP7166512B2
(ja)
|
2016-05-03 |
2022-11-08 |
インスティチュート ナショナル デ ラ サンテ エ デ ラ ルシェルシュ メディカル (インセルム) |
炎症のイメージングのための分子標識としてのCD31shed
|
ES2912453T3
(es)
|
2016-05-06 |
2022-05-26 |
Inst Nat Sante Rech Med |
Composiciones farmacéuticas para el tratamiento de la leucemia mieloide aguda (LMA) quimiorresistente
|
US20190151346A1
(en)
|
2016-05-10 |
2019-05-23 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
EP3463452A1
(en)
|
2016-05-24 |
2019-04-10 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
|
WO2017202890A1
(en)
|
2016-05-27 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating myeloma
|
WO2018007442A1
(en)
|
2016-07-06 |
2018-01-11 |
Ablynx N.V. |
Treatment of il-6r related diseases
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
KR20230079499A
(ko)
|
2016-08-05 |
2023-06-07 |
추가이 세이야쿠 가부시키가이샤 |
Il-8 관련 질환의 치료용 또는 예방용 조성물
|
WO2018029182A1
(en)
|
2016-08-08 |
2018-02-15 |
Ablynx N.V. |
Il-6r single variable domain antibodies for treatment of il-6r related diseases
|
WO2018035046A1
(en)
|
2016-08-15 |
2018-02-22 |
President And Fellows Of Harvard College |
Treating infections using idsd from proteus mirabilis
|
WO2018041989A1
(en)
|
2016-09-02 |
2018-03-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating refractory celiac disease type 2
|
JP6644956B2
(ja)
*
|
2016-09-07 |
2020-02-12 |
サクシン ライフサイエンシス ピーヴィーティー エルティディーSaksin Lifesciences Pvt Ltd |
Vegfに対する合成の抗体およびそれらの使用
|
EP3510407A1
(en)
|
2016-09-08 |
2019-07-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating nephrotic syndrome
|
WO2018050833A1
(en)
|
2016-09-15 |
2018-03-22 |
Ablynx Nv |
Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
US20190345500A1
(en)
|
2016-11-14 |
2019-11-14 |
|Nserm (Institut National De La Santé Et De La Recherche Médicale) |
Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
|
WO2018091606A1
(en)
|
2016-11-16 |
2018-05-24 |
Ablynx Nv |
T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
|
EP3541830A1
(en)
|
2016-11-17 |
2019-09-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for increasing endogenous protein level
|
WO2018099968A1
(en)
|
2016-11-29 |
2018-06-07 |
Ablynx N.V. |
Treatment of infection by respiratory syncytial virus (rsv)
|
EP3548894B1
(en)
|
2016-12-02 |
2021-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for diagnosing renal cell carcinoma
|
WO2018134389A1
(en)
|
2017-01-23 |
2018-07-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating infections
|
WO2018146253A1
(en)
|
2017-02-10 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
|
EP3589725A1
(en)
|
2017-02-28 |
2020-01-08 |
Vib Vzw |
Means and methods for oral protein delivery
|
WO2018169785A2
(en)
|
2017-03-13 |
2018-09-20 |
The Government Of The United States Of America As Represented By The Secretary Of The Army |
Therapeutic antibodies to marburg virus
|
WO2018172508A1
(en)
|
2017-03-24 |
2018-09-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2018178029A1
(en)
|
2017-03-27 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
|
WO2018178030A1
(en)
|
2017-03-27 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
|
US20200031891A1
(en)
|
2017-03-28 |
2020-01-30 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
New tau species
|
WO2018178237A1
(en)
|
2017-03-30 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of mitochondrial genetic diseases
|
WO2018203545A1
(ja)
|
2017-05-02 |
2018-11-08 |
国立研究開発法人国立精神・神経医療研究センター |
Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
|
CA3062238A1
(en)
|
2017-05-11 |
2018-11-15 |
Vib Vzw |
Glycosylation of variable immunoglobulin domains
|
CA3062981A1
(en)
|
2017-05-17 |
2018-11-22 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Flt3 inhibitors for improving pain treatments by opioids
|
RU2022108410A
(ru)
*
|
2017-05-24 |
2022-04-05 |
ЭйЭлЭс ТЕРАПИ ДЕВЕЛОПМЕНТ ИНСТИТЬЮТ |
Терапевтические антитела против лиганда cd40
|
WO2018220235A1
(en)
|
2017-06-02 |
2018-12-06 |
Merck Patent Gmbh |
Mmp13 binding immunoglobulins
|
BR112019024333A2
(pt)
|
2017-06-02 |
2020-07-28 |
Merck Patent Gmbh |
imunoglobulinas de ligação adamts
|
KR20200013247A
(ko)
|
2017-06-02 |
2020-02-06 |
아블린쓰 엔.브이. |
아그레칸 결합 면역글로불린
|
US11813307B2
(en)
|
2017-06-02 |
2023-11-14 |
Merck Patent Gmbh |
Polypeptides binding ADAMTS5, MMP13 and aggrecan
|
EP3634582A1
(en)
|
2017-06-08 |
2020-04-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating hyperpigmentation disorders
|
JP7265487B2
(ja)
|
2017-06-08 |
2023-04-26 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
関心対象のアナライトを検出するための全細胞センサにおいて使用するためのキメラ受容体
|
WO2018234843A1
(en)
|
2017-06-22 |
2018-12-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS WITH AGENTS CAPABLE OF INHIBITING THE ACTIVATION OF MOSES-ASSOCIATED INVARIANT T CELLS (MAIT)
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
WO2019002548A1
(en)
|
2017-06-29 |
2019-01-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
TREATMENT OF MIGRAINE WITH TREK1, TREK2 AGONIZATION OR HETEROMERS COMPRISING SAME
|
KR102625929B1
(ko)
|
2017-07-19 |
2024-01-16 |
브이아이비 브이지더블유 |
혈청 알부민 결합제
|
WO2019016310A1
(en)
|
2017-07-20 |
2019-01-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND COMPOSITIONS FOR TREATING CANCERS
|
US11174322B2
(en)
|
2017-07-24 |
2021-11-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies and peptides to treat HCMV related diseases
|
WO2019020593A1
(en)
|
2017-07-25 |
2019-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF MONOCYTOPOISIS
|
WO2019043026A1
(en)
|
2017-08-30 |
2019-03-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
ANTI-MESOTHELIC RADIOMARQUATED SINGLE DOMAIN ANTIBODIES SUITABLE FOR IMAGING AND TREATING CANCERS
|
EP3457139A1
(en)
|
2017-09-19 |
2019-03-20 |
Promise Advanced Proteomics |
Antibody-like peptides for quantifying therapeutic antibodies
|
EA202090791A1
(ru)
|
2017-09-19 |
2020-06-17 |
Мэб Дискавери Гмбх |
Агонистические антитела против cd40
|
CN111655340A
(zh)
|
2017-09-20 |
2020-09-11 |
国家医疗保健研究所 |
用于调节自噬的方法和药物组合物
|
WO2019086548A1
(en)
|
2017-10-31 |
2019-05-09 |
Vib Vzw |
Novel antigen-binding chimeric proteins and methods and uses thereof
|
US11787874B2
(en)
|
2017-11-15 |
2023-10-17 |
Novo Nordisk A/S |
Factor X binders enhancing FX activation
|
WO2019101995A1
(en)
|
2017-11-27 |
2019-05-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for cardiac regeneration
|
KR20200104333A
(ko)
|
2017-12-28 |
2020-09-03 |
난징 레전드 바이오테크 씨오., 엘티디. |
Tigit에 대한 단일-도메인 항체 및 이의 변이체
|
EP3735590A1
(en)
|
2018-01-04 |
2020-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma resistant
|
CA3084518A1
(en)
|
2018-01-15 |
2019-07-18 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against pd-1
|
EP3743096A1
(en)
|
2018-01-25 |
2020-12-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antagonists of il-33 for use in methods for preventing ischemia reperfusion injury in an organ
|
SG11202006902QA
(en)
|
2018-02-06 |
2020-08-28 |
Ablynx Nv |
Methods of treating initial episode of ttp with immunoglobulin single variable domains
|
JP7384811B2
(ja)
|
2018-02-16 |
2023-11-21 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
白斑を処置するための方法及び組成物
|
JP2021514649A
(ja)
|
2018-03-01 |
2021-06-17 |
ブレイエ・ユニバージテイト・ブリュッセルVrije Universiteit Brussel |
ヒトpd−l1結合免疫グロブリン
|
CA3088676A1
(en)
|
2018-03-23 |
2019-09-26 |
Universite Libre De Bruxelles |
Wnt signaling agonist molecules
|
US11958903B2
(en)
|
2018-03-30 |
2024-04-16 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against LAG-3 and uses thereof
|
WO2019193375A1
(en)
|
2018-04-04 |
2019-10-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of fzd7 inhibitors for the treatment of retinal neovascularization
|
WO2019207030A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
|
CN112654397A
(zh)
|
2018-09-05 |
2021-04-13 |
国家医疗保健研究所 |
用于治疗哮喘和过敏性疾病的方法和组合物
|
US20220048995A1
(en)
|
2018-09-10 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of an inhibitor of ntsr1 activation or expression for preventing weight loss, muscle loss, and protein blood level decrease in subjects in need thereof
|
EP3849545A1
(en)
|
2018-09-10 |
2021-07-21 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for the treatment of neurofibromatosis
|
US20220023265A1
(en)
|
2018-09-17 |
2022-01-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of phosphatase activity of soluble epoxide for the treatment of cardiometabolic diseases
|
WO2020058372A1
(en)
|
2018-09-19 |
2020-03-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
US20220033486A1
(en)
|
2018-09-25 |
2022-02-03 |
Inserm (Institut National De La Santè Et De La Recherch Médicale) |
Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
|
WO2020070062A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
|
JP2022512626A
(ja)
|
2018-10-04 |
2022-02-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
粘膜炎症性疾患の処置のための方法及び医薬組成物
|
US20210355216A1
(en)
|
2018-10-05 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and systems for controlling the agonistic properties of antibody variable domains by light
|
EP3636657A1
(en)
|
2018-10-08 |
2020-04-15 |
Ablynx N.V. |
Chromatography-free antibody purification method
|
JP2022512648A
(ja)
|
2018-10-09 |
2022-02-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
心筋線維化の処置のためのαV-インテグリン(CD51)阻害剤の使用
|
WO2020079162A1
(en)
|
2018-10-18 |
2020-04-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for inducing full ablation of hematopoiesis
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
WO2020115261A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2020120592A1
(en)
|
2018-12-12 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating melanoma
|
US20220017611A1
(en)
|
2018-12-13 |
2022-01-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New anti tau svqivykpv epitope single domain antibody
|
WO2020127885A1
(en)
|
2018-12-21 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating cancers and resistant cancers
|
WO2020141199A1
(en)
|
2019-01-03 |
2020-07-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
|
US20220117911A1
(en)
|
2019-02-04 |
2022-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating blood-brain barrier
|
WO2020169707A1
(en)
|
2019-02-21 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Foxo1 inhibitor for use in the treatment of latent virus infection
|
WO2020178313A1
(en)
|
2019-03-05 |
2020-09-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New biomarkers and biotargets in renal cell carcinoma
|
EP4378485A2
(en)
|
2019-03-08 |
2024-06-05 |
LinXis B.V. |
Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
|
US20220177558A1
(en)
|
2019-03-25 |
2022-06-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Treatment of taupathy disorders by targeting new tau species
|
EP3946330A1
(en)
|
2019-03-29 |
2022-02-09 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
|
WO2020201362A2
(en)
|
2019-04-02 |
2020-10-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
WO2020201442A1
(en)
|
2019-04-03 |
2020-10-08 |
Orega Biotech |
Combination therapies based on pd1 and il-17b inhibitors
|
US20220220565A1
(en)
|
2019-04-30 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
US11434291B2
(en)
|
2019-05-14 |
2022-09-06 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
US20220220197A1
(en)
|
2019-05-28 |
2022-07-14 |
Vib Vzw |
Cancer Treatment by Targeting Plexins in the Immune Compartment
|
US20220228116A1
(en)
|
2019-05-28 |
2022-07-21 |
Vib Vzw |
Cd8+ t-cells lacking plexins and their application in cancer treatment
|
US20220259295A1
(en)
|
2019-06-20 |
2022-08-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method useful in tolerance induction therapy and kits therefore
|
WO2021023644A1
(en)
|
2019-08-02 |
2021-02-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neutralizing granzyme b for providing cardioprotection in a subject who experienced a myocardial infarction
|
WO2021048292A1
(en)
|
2019-09-11 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2021063968A1
(en)
|
2019-09-30 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and composition for diagnosing chronic obstructive pulmonary disease
|
EP4037714A1
(en)
|
2019-10-03 |
2022-08-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating macrophages polarization
|
US20220363776A1
(en)
|
2019-10-04 |
2022-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
WO2021078359A1
(en)
|
2019-10-21 |
2021-04-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of cubilin for the treatment of chronic kidney diseases
|
US20220390449A1
(en)
|
2019-11-12 |
2022-12-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New serological marker for the latent form of toxoplasmosis
|
GB201918279D0
(en)
|
2019-12-12 |
2020-01-29 |
Vib Vzw |
Glycosylated single chain immunoglobulin domains
|
EP4090770A1
(en)
|
2020-01-17 |
2022-11-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
JP2023514957A
(ja)
|
2020-02-28 |
2023-04-12 |
オレガ・バイオテック |
Ctla4阻害剤及びil-17b阻害剤に基づく複合療法
|
BR112022019728A2
(pt)
|
2020-03-31 |
2022-11-22 |
Biotalys NV |
Polipeptídeos antifúngicos
|
WO2021198511A1
(en)
|
2020-04-03 |
2021-10-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of sars-cov-2 infection
|
US20230279115A1
(en)
|
2020-04-22 |
2023-09-07 |
Mabwell (shanghai) Bioscience Co., Ltd. |
Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof
|
WO2021224401A1
(en)
|
2020-05-07 |
2021-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for determining a reference range of β-galactose exposure platelet
|
KR20230008751A
(ko)
|
2020-05-12 |
2023-01-16 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
피부 t-세포 림프종 및 tfh 유래된 림프종을 치료하는 신규한 방법
|
WO2021229104A1
(en)
|
2020-05-15 |
2021-11-18 |
Université de Liège |
Anti-cd38 single-domain antibodies in disease monitoring and treatment
|
WO2021234110A1
(en)
|
2020-05-20 |
2021-11-25 |
Institut Curie |
Single domain antibodies and their use in cancer therapies
|
CA3182339A1
(en)
|
2020-05-20 |
2021-11-25 |
Institut Curie |
Synthetic single domain library
|
WO2021245224A1
(en)
|
2020-06-05 |
2021-12-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating ocular diseases
|
US12006366B2
(en)
|
2020-06-11 |
2024-06-11 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
TW202214844A
(zh)
|
2020-06-17 |
2022-04-16 |
美商健生生物科技公司 |
用於製造多能幹細胞之材料及方法
|
JP2023532726A
(ja)
|
2020-06-29 |
2023-07-31 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) |
抗プロテインsシングルドメイン抗体及びそれを含むポリペプチド
|
WO2022008597A1
(en)
|
2020-07-08 |
2022-01-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of infectious diseases
|
WO2022023379A1
(en)
|
2020-07-28 |
2022-02-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for preventing and treating a cancer
|
US20230323299A1
(en)
|
2020-08-03 |
2023-10-12 |
Inserm (Institut National De La Santé Et De La Recherch Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
WO2022060223A1
(en)
|
2020-09-16 |
2022-03-24 |
Linxis B.V. |
Internalizing binding molecules
|
WO2022063957A1
(en)
|
2020-09-24 |
2022-03-31 |
Vib Vzw |
Biomarker for anti-tumor therapy
|
WO2022063947A1
(en)
|
2020-09-24 |
2022-03-31 |
Vib Vzw |
Combination of p2y6 inhibitors and immune checkpoint inhibitors
|
WO2022064049A1
(en)
|
2020-09-28 |
2022-03-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for diagnosing brucella infection
|
EP4229090A1
(en)
|
2020-10-16 |
2023-08-23 |
Université d'Aix-Marseille |
Anti-gpc4 single domain antibodies
|
WO2022084300A1
(en)
|
2020-10-20 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosis and monitoring form of coronavirus infection
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
EP4240761A1
(en)
|
2020-11-05 |
2023-09-13 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of il-6 inhibitors for the treatment of acute chest syndrome in patients suffering from sickle cell disease
|
EP4244391A1
(en)
|
2020-11-16 |
2023-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
IL303373A
(en)
|
2020-12-04 |
2023-08-01 |
Tidal Therapeutics Inc |
Ionized cationic lipids and lipid nanoparticles, and methods of their synthesis and use
|
TW202222840A
(zh)
|
2020-12-11 |
2022-06-16 |
大陸商上海華奧泰生物藥業股份有限公司 |
Cd73的抗原結合蛋白及其應用
|
BR112023013790A2
(pt)
|
2021-01-11 |
2023-10-03 |
Starmab Biologics Suzhou Co Ltd |
Proteína de ligação a antígeno dirigida à alfa-toxina de staphylococcus aureus e aplicação da mesma
|
KR20230132511A
(ko)
|
2021-01-13 |
2023-09-15 |
상하이 후아오타 바이오파마슈티컬 컴퍼니 리미티드 |
Cd73에 결합하는 단백질 및 이의 용도
|
CN117916271A
(zh)
|
2021-01-14 |
2024-04-19 |
居里研究所 |
Her2单域抗体变体及其car
|
EP4282413A1
(en)
|
2021-01-21 |
2023-11-29 |
Natural Medicine Institute Of Zhejiang Yangshengtang Co., Ltd. |
Composition and method for treating tumors
|
MX2023009100A
(es)
|
2021-02-03 |
2023-09-25 |
Mozart Therapeutics Inc |
Agentes aglutinantes y métodos para usar los mismos.
|
CA3211257A1
(en)
|
2021-02-17 |
2022-08-25 |
Vib Vzw |
Inhibition of slc4a4 in the treatment of cancer
|
KR20220118962A
(ko)
|
2021-02-19 |
2022-08-26 |
(주)샤페론 |
Pd-l1에 대한 단일 도메인 항체 및 이의 용도
|
CN116917322A
(zh)
|
2021-02-19 |
2023-10-20 |
沙裴隆有限公司 |
针对pd-l1及cd47的双特异性单域抗体及其用途
|
WO2022177392A1
(ko)
|
2021-02-19 |
2022-08-25 |
(주)샤페론 |
Cd47에 대한 단일 도메인 항체 및 이의 용도
|
WO2022178255A2
(en)
|
2021-02-19 |
2022-08-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that neutralize sars-cov-2
|
US20240165094A1
(en)
|
2021-03-17 |
2024-05-23 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating melanoma
|
KR20230162797A
(ko)
|
2021-03-22 |
2023-11-28 |
스타맵 바이오로직스 (쑤저우) 씨오., 엘티디 |
뉴몰리신을 표적으로 하는 항원 결합 단백질 및 이의 용도
|
US20240175873A1
(en)
|
2021-03-23 |
2024-05-30 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
EP4299593A1
(en)
|
2021-04-02 |
2024-01-03 |
Oricell Therapeutics Co., Ltd. |
Cldn18.2 antigen-binding protein and use thereof
|
WO2022214681A1
(en)
|
2021-04-09 |
2022-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
WO2022223488A1
(en)
|
2021-04-19 |
2022-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of splice switching oligonucleotides for exon skipping-mediated knockdown of pim2
|
US20240158861A1
(en)
|
2021-04-23 |
2024-05-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
WO2022242892A1
(en)
|
2021-05-17 |
2022-11-24 |
Université de Liège |
Anti-cd38 single-domain antibodies in disease monitoring and treatment
|
WO2022269473A1
(en)
|
2021-06-23 |
2022-12-29 |
Janssen Biotech, Inc. |
Materials and methods for hinge regions in functional exogenous receptors
|
WO2023281120A1
(en)
|
2021-07-09 |
2023-01-12 |
Luxembourg Institute Of Health (Lih) |
Dimeric protein complexes and uses thereof
|
WO2023285362A1
(en)
|
2021-07-12 |
2023-01-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of il-36 inhibitors for the treatment of netherton syndrome
|
KR20240038768A
(ko)
|
2021-07-30 |
2024-03-25 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
키메라 단백질 및 면역치료 방법
|
WO2023057601A1
(en)
|
2021-10-06 |
2023-04-13 |
Biotalys NV |
Anti-fungal polypeptides
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
WO2023078900A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
WO2023118165A1
(en)
|
2021-12-21 |
2023-06-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
EP4209508A1
(en)
|
2022-01-11 |
2023-07-12 |
Centre national de la recherche scientifique |
Nanobodies for the deneddylating enzyme nedp1
|
WO2023144235A1
(en)
|
2022-01-27 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
EP4231017A1
(en)
|
2022-02-17 |
2023-08-23 |
Promise Proteomics |
Detection and quantification of anti-drug antibodies and anti-self antibodies
|
EP4257609A1
(en)
|
2022-04-08 |
2023-10-11 |
iOmx Therapeutics AG |
Combination therapies based on pd-1 inhibitors and sik3 inhibitors
|
WO2023198648A1
(en)
|
2022-04-11 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
WO2023198851A1
(en)
|
2022-04-14 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for controlling the tumor cell killing by light
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
WO2023217904A1
(en)
|
2022-05-10 |
2023-11-16 |
Institut National de la Santé et de la Recherche Médicale |
Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
|
US20240002331A1
(en)
|
2022-06-08 |
2024-01-04 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
WO2023237661A1
(en)
|
2022-06-09 |
2023-12-14 |
Institut National de la Santé et de la Recherche Médicale |
Use of endothelin receptor type b agonists for the treatment of aortic valve stenosis
|
EP4299124A1
(en)
|
2022-06-30 |
2024-01-03 |
Universite De Montpellier |
Anti-mglur2 nanobodies for use as biomolecule transporter
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
WO2024008755A1
(en)
|
2022-07-04 |
2024-01-11 |
Vib Vzw |
Blood-cerebrospinal fluid barrier crossing antibodies
|
WO2024008274A1
(en)
|
2022-07-04 |
2024-01-11 |
Universiteit Antwerpen |
T regulatory cell modification
|
WO2024008799A1
(en)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of proliferative glomerulonephritis
|
WO2024013234A1
(en)
|
2022-07-13 |
2024-01-18 |
Institut National de la Santé et de la Recherche Médicale |
Methods for diagnosis, prognosis, stratification and treating of myocarditis
|
WO2024018003A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Extracellular vesicles functionalized with an erv syncitin and uses thereof for cargo delivery
|
WO2024018046A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
WO2024018426A1
(en)
|
2022-07-22 |
2024-01-25 |
Janssen Biotech, Inc. |
Enhanced transfer of genetic instructions to effector immune cells
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
WO2024028433A1
(en)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|
WO2024033400A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sk2 inhibitor for the treatment of pancreatic cancer
|
WO2024033399A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sigmar1 ligand for the treatment of pancreatic cancer
|
WO2024038112A1
(en)
|
2022-08-17 |
2024-02-22 |
Institut National de la Santé et de la Recherche Médicale |
Improved anti-albumin nanobodies and their uses
|
WO2024047110A1
(en)
|
2022-08-31 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate more efficient car-t cells
|
WO2024074713A1
(en)
|
2022-10-07 |
2024-04-11 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate improving car-t cells
|
WO2024079192A1
(en)
|
2022-10-12 |
2024-04-18 |
Institut National de la Santé et de la Recherche Médicale |
Cd81 as a biomarker and biotarget in t-cell malignancies
|
WO2024083843A1
(en)
|
2022-10-18 |
2024-04-25 |
Confo Therapeutics N.V. |
Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
|
WO2024084034A1
(en)
|
2022-10-21 |
2024-04-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of osteoarthritis
|
WO2024115935A1
(en)
|
2022-11-29 |
2024-06-06 |
Inserm |
Methods for the treatment of b-cell lymphoma using cd39 inhibitors
|